ArticleDiscover oncology2025
Development and validation of nomogram model predicting overall survival and cancer specific survival in glioblastoma patients.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multilayered insights into the full spectrum of diffuse gliomas: a novel prognostic evaluation model.Discover oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundIdentifying the incidence and risk factors of Glioblastoma (GBM) and establishing effective predictive models will benefit the management of these patients.
methodsUsing GBM data from the Surveillance, Epidemiology, and End Results (SEER) database, we used Joinpoint software to assess trends in GBM incidence across populations of different age groups. Subsequently, we identified important prognostic factors by stepwise regression and multivariate Cox regression analysis, and established a Nomogram mathematical model. COX regression model combined with restricted cubic splines (RCS) model was used to analyze the relationship between tumor size and prognosis of GBM patients.
resultsThe incidence of GBM has been on the rise since 1978, especially in the age group of 65-84 years. 11498 patients with GBM were included in our study. The multivariate Cox analysis revealed that age, tumor size, sex, primary tumor site, laterality, number of primary tumors, surgery, chemotherapy, radiotherapy, systematic therapy, marital status, median household income, first malignant primary indicator were independent prognostic factors of overall survival (OS) for GBMs. For cancer-specific survival (CSS), race is also independent prognostic factors. Additionally, risk of poor prognosis increased significantly with tumor size in patients with tumors smaller than 49 mm. Moreover, our nomogram model showed favorable discriminative ability.
conclusionAt the population level, the incidence of GBM is on the rise. The relationship between tumor size and patient prognosis is still worthy of further study. Moreover, the proposed nomogram with good performance was constructed and verified to predict the OS and CSS of patients with GBM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.